journal
MENU ▼
Read by QxMD icon Read
search

ESMO Open

journal
https://www.readbyqxmd.com/read/29765774/how-shall-we-treat-early-triple-negative-breast-cancer-tnbc-from-the-current-standard-to-upcoming-immuno-molecular-strategies
#1
REVIEW
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim
Triple-negative breast cancer (TNBC) is a long-lasting orphan disease in terms of little therapeutic progress during the past several decades and still the standard of care remains chemotherapy. Experimental discovery of molecular signatures including the 'BRCAness' highlighted the innate heterogeneity of TNBC, generating the diversity of TNBC phenotypes. As it contributes to enhancing genomic instability, it has widened the therapeutic spectrum of TNBC. In particular, unusual sensitivity to DNA damaging agents was denoted in patients with BRCA deficiency, suggesting therapeutic benefit from platinum and poly(ADP-ribose) polymerase inhibitors...
2018: ESMO Open
https://www.readbyqxmd.com/read/29765773/optimising-the-use-of-cetuximab-in-the-continuum-of-care-for-patients-with-metastatic-colorectal-cancer
#2
REVIEW
Richard M Goldberg, Clara Montagut, Zev A Wainberg, Philippe Ronga, François Audhuy, Julien Taieb, Sebastian Stintzing, Salvatore Siena, Daniele Santini
The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs when tumours develop resistance to a therapy, although controversy remains about whether PD on a combination of chemotherapy and targeted agents implies resistance to both components. Here, we propose that some patients may gain additional clinical benefit from the reuse of cetuximab after having PD on regimens including cetuximab in an earlier treatment line...
2018: ESMO Open
https://www.readbyqxmd.com/read/29765772/nutrition-in-patients-with-cancer-a-new-area-for-medical-oncologists-a-practising-oncologist-s-interdisciplinary-position-paper
#3
EDITORIAL
Stefan Rauh, Andrea Antonuzzo, Paolo Bossi, Robert Eckert, Marie Fallon, Anna Fröbe, Silvia Gonella, Raffaele Giusti, Gabor Lakatos, Daniele Santini, Anna Villarini
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29765771/reduction-in-nephrotoxicities-using-short-hydration-for-chemotherapy-containing-cisplatin-a-consecutive-analysis-of-467-patients-with-thoracic-malignancies
#4
Midori Tanaka, Hidehito Horinouchi, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe
Background: Conventional hydration (CH) in chemotherapy containing cisplatin (CDDP) has been recommended to prevent renal toxicity. Although an increasing number of studies have demonstrated the feasibility of short hydration (SH), few large studies have reported the superiority of SH, compared with CH, in terms of nephrotoxicities. Methods: We conducted a consecutive retrospective analysis of 467 patients who had been treated with chemotherapy including CDDP. Statistical analyses were performed to evaluate the risk factors for nephrotoxicities...
2018: ESMO Open
https://www.readbyqxmd.com/read/29719730/controversies-in-oncology-surgery-for-small-cell-lung-cancer-it-s-time-to-rethink-the-case
#5
EDITORIAL
Mir Alireza Hoda, Thomas Klikovits, Walter Klepetko
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29713501/management-of-recurrent-or-metastatic-thyroid-cancer
#6
Makoto Tahara
Recently, vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) have become available for the treatment of recurrent or metastatic thyroid cancer. However, a number of clinical challenges that impact the use of VEGFR-targeted TKI in daily clinical practice have arisen. Toxicity is considerable, to the extent that most physicians hesitate to start VEGFR-targeted TKI and prefer to continue a watch-and-wait approach until the patient's disease markedly worsens. This delayed use of VEGFR-targeted TKI leads to a higher incidence of serious adverse events than was reported in clinical trials...
2018: ESMO Open
https://www.readbyqxmd.com/read/29713500/new-data-new-options-for-front-line-therapy-in-nsclc
#7
EDITORIAL
Niels Reinmuth
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29713499/safety-data-from-the-phase-iii-japanese-achieve-trial-part-of-an-international-prospective-planned-pooled-analysis-of-six-phase-iii-trials-comparing-3-versus-6-months-of-oxaliplatin-based-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#8
Masahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Makio Gamoh, Manabu Shiozawa, Shigetoyo Saji, Yoshihiko Maehara, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori
Background: The International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part of this project, we report safety data from the Japanese ACHIEVE study (JFMC47-1202-C3). Patients and methods: ACHIEVE was an open-label, multicentre trial randomising patients with stage III colon cancer to receive 3 m or 6 m of mFOLFOX6/CAPOX after surgery...
2018: ESMO Open
https://www.readbyqxmd.com/read/29713498/association-of-baseline-absolute-neutrophil-counts-and-survival-in-patients-with-metastatic-colorectal-cancer-treated-with-second-line-antiangiogenic-therapies-exploratory-analyses-of-the-raise-trial-and-validation-in-an-electronic-medical-record-data-set
#9
Axel Grothey, Takayuki Yoshino, Gyorgy Bodoky, Tudor Ciuleanu, Rocio Garcia-Carbonero, Pilar García-Alfonso, Eric Van Cutsem, Kei Muro, Daniel S Mytelka, Li Li, Olga Lipkovich, Yanzhi Hsu, Andreas Sashegyi, David Ferry, Federico Nasroulah, Josep Tabernero
Background: In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. Thus, we conducted an exploratory post-hoc analysis of RAISE and a retrospective, observational analysis of electronic medical record (EMR) data to determine and verify the association of neutropaenia, baseline absolute neutrophil count (ANC) and survival...
2018: ESMO Open
https://www.readbyqxmd.com/read/29683152/response-effects-of-physical-activity-on-depressive-symptoms-during-breast-cancer-survivorship-a-meta-analysis-of-randomised-control-trials
#10
COMMENT
Efrossini D Patsou, Michalis V Karamouzis
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29682333/in-the-literature-april-2018
#11
Valentina Gambardella, Gemma Bruixola, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29682332/gender-and-outcomes-in-non-small-cell-lung-cancer-an-old-prognostic-variable-comes-back-for-targeted-therapy-and-immunotherapy
#12
Joseph A Pinto, Carlos S Vallejos, Luis E Raez, Luis A Mas, Rossana Ruiz, Junior S Torres-Roman, Zaida Morante, Jhajaira M Araujo, Henry L Gómez, Alfredo Aguilar, Denisse Bretel, Claudio J Flores, Christian Rolfo
Background: There are well-known differences in gender outcome in non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the gender influence in the outcome of patients with NSCLC treated with targeted therapy and immunotherapy. Methods: We performed a series of meta-analysis to compare the gender outcome in the routine setting for overall survival and progression-free survival (PFS) in phase III randomised clinical trials comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, LUX-lung 6, EURTAC, ENSURE and WTJOG); ALK inhibitors versus chemotherapy (ASCEND 4, ASCEND 5, PROFILE 1014 and NCT009323893) and anti-PD1 checkpoint inhibitors versus chemotherapy (CheckMate 017, CheckMate 026, CheckMate 057, KEYNOTE 010 and KEYNOTE 024)...
2018: ESMO Open
https://www.readbyqxmd.com/read/29682331/-brca-mutation-carrier-detection-a-model-based-cost-effectiveness-analysis-comparing-the-traditional-family-history-approach-and-the-testing-of-all-patients-with-breast-cancer
#13
Jan Norum, Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Dag Erik Undlien, Ellen Schlichting, Lovise Mæhle
Background: Identification of BRCA mutation carriers among patients with breast cancer (BC) involves costs and gains. Testing has been performed according to international guidelines, focusing on family history (FH) of breast and/or ovarian cancer. An alternative is testing all patients with BC employing sequencing of the BRCA genes and Multiplex Ligation Probe Amplification (MLPA). Patients and methods: A model-based cost-effectiveness analysis, employing data from Oslo University Hospital, Ullevål (OUH-U) and a decision tree, was done...
2018: ESMO Open
https://www.readbyqxmd.com/read/29644102/extrapolation-concept-at-work-with-biosimilar-a-decade-of-experience-in-oncology
#14
EDITORIAL
Andriy Krendyukov, Martin Schiestl
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29636992/controversies-in-oncology-which-adjuvant-endocrine-therapy-is-to-be-given-to-premenopausal-patients-with-hormone-receptor-positive-breast-cancer
#15
EDITORIAL
Matteo Lambertini, Giulia Viglietti, Evandro de Azambuja
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29636991/relevance-of-a-molecular-tumour-board-mtb-for-patients-enrolment-in-clinical-trials-experience-of-the-institut-curie
#16
Clémence Basse, Claire Morel, Marie Alt, Marie Paule Sablin, Coralie Franck, Gaëlle Pierron, Céline Callens, Samia Melaabi, Julien Masliah-Planchon, Guillaume Bataillon, Sophie Gardrat, Marion Lavigne, Benjamin Bonsang, Pauline Vaflard, Elvire Pons Tostivint, Coraline Dubot, Delphine Loirat, Miguelle Marous, Romain Geiss, Nathalie Clément, Gudrun Schleiermacher, Choumouss Kamoun, Elodie Girard, Maude Ardin, Camille Benoist, Virginie Bernard, Odette Mariani, Roman Rouzier, Patricia Tresca, Vincent Servois, Anne Vincent-Salomon, Ivan Bieche, Christophe Le Tourneau, Maud Kamal
Background: High throughput molecular screening techniques allow the identification of multiple molecular alterations, some of which are actionable and can be targeted by molecularly targeted agents (MTA). We aimed at evaluating the relevance of using this approach in the frame of Institut Curie Molecular Tumor Board (MTB) to guide patients with cancer to clinical trials with MTAs. Patients and methods: We included all patients presented at Institut Curie MTB from 4 October 2014 to 31 October 2017...
2018: ESMO Open
https://www.readbyqxmd.com/read/29636990/recent-advances-in-adjuvant-therapy-for-patients-with-melanoma
#17
Jeffrey Weber
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29636989/comprehensive-molecular-screening-by-next-generation-sequencing-reveals-a-distinctive-mutational-profile-of-kit-pdgfra-genes-and-novel-genomic-alterations-results-from-a-20-year-cohort-of-patients-with-gist-from-north-western-greece
#18
Leonidas Mavroeidis, Vassiliki Metaxa-Mariatou, Alexandra Papoudou-Bai, Angeliki Maria Lampraki, Lida Kostadima, Ilias Tsinokou, George Zarkavelis, Alexandra Papadaki, Dimitrios Petrakis, Stefania Gκoura, Eleftherios Kampletsas, George Nasioulas, Anna Batistatou, George Pentheroudakis
Introduction: Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms that usually carry an activating mutation in KIT or platelet-derived growth factor receptor alpha ( PDGFRA ) genes with predictive and prognostic significance. We investigated the extended mutational status of GIST in a patient population of north-western Greece in order to look at geopraphic/genotypic distinctive traits. Patient and methods: Clinicopathological and molecular data of 38 patients diagnosed from 1996 to 2016 with GIST in the region of Epirus in Greece were retrospectively assessed...
2018: ESMO Open
https://www.readbyqxmd.com/read/29636988/four-distinct-immune-microenvironment-subtypes-in-gastric-adenocarcinoma-with-special-reference-to-microsatellite-instability
#19
Junhun Cho, Young Hwan Chang, You Jeong Heo, Seungtae Kim, Nayoung Kd Kim, Joon Oh Park, Won Ki Kang, Jeeyun Lee, Kyoung-Mee Kim
Introduction: Programmed death-ligand 1 (PD-L1) can be overexpressed in tumours other than Epstein-Barr virus (EBV)-positive (EBV+ ) or microsatellite instability-high (MSI-H) gastric cancer (GC) subtypes. We aimed to determine the tumour immune microenvironment (TME) classification of GC to better understand tumour-immune interactions and help patient selection for future immunotherapy with special reference to MSI-H. Methods: Immunohistochemistry (IHC) for PD-L1 and CD8+ T cells in three distinct subtypes of GC (43 EBV+ , 79 MSI-H and 125 EBV- /MSS) were performed and analysed...
2018: ESMO Open
https://www.readbyqxmd.com/read/29636987/consensus-on-management-of-metastatic-colorectal-cancer-in-central-america-and-the-caribbean-san-jos%C3%A3-costa-rica-august-2016
#20
REVIEW
Roberto Ivan López, Jenny Lissette Castro, Heidy Cedeño, Dagoberto Cisneros, Luis Corrales, Ileana González-Herrera, Mayté Lima-Pérez, Rogelio Prestol, Roberto Salinas, Jorge Luis Soriano-García, Alejandra T Zavala, Luis Miguel Zetina, Carlos Eduardo Zúñiga-Orlich
Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient...
2018: ESMO Open
journal
journal
53848
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"